MedTrace Logo

IMX-150 Cream for Diabetic Neuropathy

NCT00641953 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2008-06-17

No results posted yet for this study

Summary

The purpose of this study is to compare the effectiveness of two different dose of IMX-150 to that of placebo (non-active) in the treatment of diabetic peripheral neuropathy pain of the feet.

Conditions

  • Diabetic Peripheral Neuropathy

Interventions

DRUG

IMX-150

(0.3%) 0.5g topically BID to each foot for 4 weeks

DRUG

IMX-150

(0.6%) 0.5g topically BID to each foot for 4 weeks

DRUG

Placebo

0.5 g topically BID to each foot for 4 weeks

Sponsors & Collaborators

  • Procris Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Patrick Yeramian, MD · VP Medical Affairs

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00641953 on ClinicalTrials.gov